Alembic Pharmaceuticals has received an approval for issue of Unsecured Listed Non-Convertible Debentures (NCDs) of up to Rs 300 crore on Private Placement Basis. The Board of Directors of the company at its meeting held on September 10, 2018, approved the same.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.